- Pharma/Biotech (6)
- Company/Commercial (5)
- Corporate (4)
- Regulatory and compliance (4)
- Competition/EU (3)
- Healthcare (3)
- Banking / Finance (2)
- Employment (2)
- Information Technology (2)
- Insolvency & restructuring (2)
- Litigation / Dispute Resolution (2)
- Real Estate (2)
- Tax (2)
- Commodities (1)
- Energy (1)
- Environment (1)
- Insurance/reinsurance (1)
- Media/Entertainment/Sport (1)
- Public Sector/Local Authority (1)
Sort By: Newest first | Oldest first
The ITC has reaffirmed its power to ban electronic transmissions from the US where those transmissions infringe an intellectual property right or are otherwise based on an unfair trade practice.
Allen & Overy has won the International Law Firm of the Year award at the second annual Law Firm of the Year competition in Slovakia.
Allen & Overy has advised Old Mutual on the sale of Skandia Germany and Skandia Austria, part of Old Mutual Wealth, to a Cinven and Hannover Re acquisition vehicle.
Federal Circuit affirms practice of reviewing trial judges’ patent claim interpretation rulings anew
The Federal Circuit has affirmed its practice of reviewing trial court claim construction rulings de novo, as a question of law.
All companies that import such products (even not named in the ITC complaint) face potential risk of Customs seizure.
Federal Circuit limits ITC authority to remedy patent infringement claims based on induced infringement
A limited exclusion order under section 337 may not be predicated on a theory of induced infringement when the subject imported product did not directly infringe before or at importation.
Allen & Overy, on behalf of the Republic of Cuba, is challenging Australia’s Tobacco Plain Packaging Act 2011 legislation.
Allen & Overy has advised Husky Injection Molding Systems on its acquisition of Schöttli Group. The sale is expected to close in early December.
Allen & Overy has advised Saudi Arabian solar company Sun & Life on the acquisition of the insolvent solar division of the Flabeg Group.
Patent cliffs remain one of the biggest issues facing the pharmaceutical industry.
A federal jury in New York has found Hebei Welcome Pharmaceutical Co and its parent liable for agreeing with other Chinese manufacturers to fix prices in the vitamin-C market.
The US Supreme Court ruled in Federal Trade Commission v Actavis that antitrust challenges to pay-for-delay agreements between drug makers should be analysed under the ‘rule of reason’.
Novartis has been awarded an interim injunction against Hospira to prevent sales of generic zoledronic acid in the UK despite Novartis’s patents having been declared invalid by the English High Court.
Intellectual property issues in the cloud continue to be one of the ‘cloudiest’ legal areas for customers and suppliers alike.